BioPharma Dive - Latest News

Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda

Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a wave of research practically overnight.

Mar 4, 2025 - 12:01
 0
Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda

Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a wave of research practically overnight.

Read More

Tags:

Previous Article

UK indie breweries to benefit from new Beer Rep podcast

Next Article

Julian Klausner sets out to prove he’s a worthy successor to Dries Van Noten

Related Posts

Aardvark prices $94M IPO to fund Prader-Willi, obesity drug work

Aardvark prices $94M IPO to fund Prader-Willi, obesity ...

Feb 13, 2025  0

Summit partners with Pfizer to study bispecific, ADC combinations

Summit partners with Pfizer to study bispecific, ADC co...

Feb 24, 2025  0

Tariffs raise concern among generic drugmakers, as advocacy groups seek exemptions

Tariffs raise concern among generic drugmakers, as advo...

Feb 10, 2025  0